Search results
Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting. Emend is used in patients aged from 6 months to prevent nausea and vomiting caused by chemotherapy (medicines used to treat cancer).
- ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS - European Medicines Agency
EMEND is given for 3 days as part of a regimen that includes...
- ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS - European Medicines Agency
EMEND należy przyjmować przez 3 dni w skojarzeniu z kortykosteroidem i antagonistą receptora 5-HT3. Zalecana dawka wynosi 125 mg, raz na dobę, podana doustnie na godzinę przed rozpoczęciem chemioterapii w 1. dniu oraz dawka 80 mg, raz na dobę, podana doustnie rano w 2. i 3. dniu.
EMEND is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose is 125 mg orally once daily one hour before start of chemotherapy on Day 1 and 80 mg orally once daily on Days 2 and 3 in the morning.
EMEND is given for 3days as part of a regimen that includes a corticosteroid and a 5-HT3antagonist. The recommended dose is 125mg orally once daily one hour before start of chemotherapy on Day1 and 80mg orally once daily on Days2and3 in the morning.
22 kwi 2024 · Expert Opinion. EMEND® 125 mg powder for oral suspension is the only licensed product containing aprepitant that is appropriate for paediatric patients under age 12. It has been reported that this product is in short supply in several of the member states in which it is licensed.
Europejska Agencja Leków (EMA) 22 lutego 2013 roku zatwierdziła zmienioną Charakterystykę Produktu Leczczniego Emend.
Co zawiera i jak działa Emend - kapsułki twarde? Zapobieganie nudnościom i wymiotom związanym z chemioterapią przeciwnowotworową o dużym i umiarkowanym ryzyku wymiotów u dorosłych i młodzieży w wieku od 12 lat. Preparat stosuje się w leczeniu skojarzonym.
